1329 GMT - AstraZeneca has a strong research-and-development engine that is still running despite recent setbacks, which bodes well for the U.K. drugmaker's long-term outlook, Bernstein analysts say in a research note. Shares in AstraZeneca have been under pressure lately and some investors are debating whether its current woes are comparable to what Swiss peer Roche experienced between 2022 and 2025, when it was punished by the market after a series of disappointing trials, the analysts say. The breadth and depth of AstraZeneca's drug pipeline means those fears seem misplaced and the U.K. company is unlikely to share Roche's fate, the analysts add. Bernstein trims its target price on AstraZeneca to 198 pounds from 200 pounds. Shares rise 1% to 120.80 pounds.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.